Results 191 to 200 of about 758,251 (341)
Low‐affinity antibodies are frequently disregarded in discovery pipelines. This work reports P5‐1C8, a Class 1 SARS‐CoV‐2 antibody with weak trimer binding (KD‐to‐IC50 > 3700‐fold) yet potent neutralization of Omicron JN.1. Structural, biophysical, functional, and coarse‐grained simulations collectively demonstrate that transient inter‐spike IgG ...
Niannian Lv +29 more
wiley +1 more source
We present a novel DNA vaccine platform featuring intrinsic, non‐targeting dsRNA that significantly enhances immune responses by activating the regulated IRE1‐dependent decay‐RIG‐I signaling pathway. This research elucidates a previously uncharacterized mechanism for dsRNA‐mediated innate immune activation.
Min‐Syuan Huang +10 more
wiley +1 more source
In Silico Identification of Antiviral Peptides as Potential Leads Against Sudan Ebolavirus VP-40. [PDF]
Omara B +12 more
europepmc +1 more source
The small-molecule antiviral compound Molnupiravir: an exploration of its tautomers.
Henry S. Rzepa
openalex +1 more source
Macrophage‐derived TRIM21 drives the progression of AP via ubiquitin‐proteasome‐mediated degradation of PHB2, leading to impaired PHB2‐mediated mitophagy. Therefore, accumulation of cytosolic mtDNA hyperactivates the cGAS‐STING signaling axis, thereby amplifying inflammatory cascades.
Yansong Xu +7 more
wiley +1 more source
Host Cell Virus Interactions: Molecular Mechanisms, Immune Modulation, Viral Pathogenesis, and Emerging Therapeutic Targets. [PDF]
Alanazi A +3 more
europepmc +1 more source
A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS? [PDF]
Saeed H. Al Marzooqi +14 more
openalex +1 more source

